The Contracts Director will oversee contract processes and negotiations, manage contracts systems, provide legal support across teams, and lead projects within the biotech company.

The Head of Biomarker Development will drive biomarker strategy for clinical programs, oversee assay development, and ensure translation from discovery to clinical phases at Scholar Rock.

The Sr. Director of Global Quality Control will lead the QC function, oversee external laboratories, and ensure compliance with global regulatory standards.

The Sr. Director of US Quality Assurance leads Quality Assurance for GxP biologics operations, ensuring compliance and strategic guidance across outsourced operations and quality processes.

The Director, Upstream MSAT & Process Development will lead efforts in developing life-changing therapies focusing on innovative treatments, with a commitment to advancing patient care through new therapeutic approaches.

The Director of Accounting Operations will manage all accounting operations, ensuring compliance and scalability while leading the accounting team and processes.

The Senior Director will lead quality systems and compliance, ensuring adherence to regulations, managing training, audits, and continuous improvement initiatives in the biopharmaceutical sector.

The VP of Global Communications will lead strategic communication initiatives, enhance company reputation, manage stakeholder engagement, and oversee internal and external messaging aligned with business priorities.

The Director of Program Management will lead the Myostatin Core Team, ensuring operational efficiency and alignment during drug development and commercialization, focusing on team effectiveness, lifecycle management, and proactive risk mitigation.

The Senior Director, HCP Marketing will develop and execute the U.S. HCP marketing strategy for Scholar Rock's first commercial launch, ensuring effective brand strategy and orchestration across marketing and sales functions.

The Director, National Accounts will lead payer engagement and establish access for Scholar Rock's investigational drug, apitegromab, focusing on patient access and coverage.